Table 3.
Characteristics of the study population with TB/HIV coinfection.
| Number | Age | TB-site | Anti-TB treatment regimens | TB-outcome | DTG-dose | HIV-RNA levels (copies/mL) | CD4 + counts (cells/µL) | ||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 48 wk | Baseline | 48 wk | ||||||
| 1 | 54 | Pulmonary | HZE + RFB | Success | 50 mg QD | 17400 | <20 | 190 | 359 |
| 2 | 31 | Pulmonary | HZE + RFB | Success | 50 mg QD | 216000 | <20 | 26 | 181 |
| 3 | 36 | Pulmonary | HZE + RFB | Success | 50 mg QD | 11900 | 59 | 277 | 481 |
| 4 | 37 | Pulmonary | HZE + RFB | Success | 50 mg QD | 47300 | <20 | 278 | 395 |
| 5 | 43 | Pulmonary | HZE + RFB | Success | 50 mg QD | 31500 | <20 | 212 | 319 |
| 6 | 58 | Pulmonary | HZE + RFB | Success | 50 mg QD | 305000 | <20 | 48 | 271 |
| 7 | 25 | Pulmonary | HZE + RFB | Success | 50 mg QD | 1400 | TND | 379 | 486 |
| 8 | 48 | Pulmonary | HZE + RFB | Success | 50 mg QD | 99000 | <20 | 36 | 212 |
| 9 | 49 | Pulmonary | HZE + RFB | Success | 50 mg QD | 36100 | <20 | 10 | 79 |
| 10 | 35 | Pulmonary | HZE + RFB | Success | 50 mg QD | 51200 | <20 | 245 | 618 |
| 11 | 28 | Pulmonary | HZE + RFB | Success | 50 mg QD | 46400 | <20 | 243 | 549 |
| 12 | 40 | Pulmonary | HZE + RFB | Success | 50 mg QD | 21700 | TND | 213 | 405 |
DTG = dolutegravir, HIV = human immunodeficiency virus, HZE = isoniazid + procaine hydrochloride + ethambutol, QD = quaque die, RFB = rifabutin, TB = tuberculosis, TND = target not.